Key Highlights:
- POMDOCTOR shares fell 25.12% to $1.52 on Friday, October 23, 2026.
- The prior close was $2.03 on October 22, consistent with the drop (calculated).
- The stock closed up 352.8% on October 21, the first session of direct Class A share trading.
- Fiscal 2025 revenue was $57.2 million with a net loss of $18.7 million.
- Market value is near $14.1 million at $1.52, based on about 9.3 million shares (calculated).
POMDOCTOR Penny Stock: What Is Behind the 25% Drop After the Share Switch?
POMDOCTOR (NASDAQ:POM) shares fell 25.12% to $1.52 on Friday, October 23, 2026. The company has not announced a catalyst for the decline.
The stock closed at $2.03 on October 22, which matches the percentage drop (calculated). On October 21 it closed up 352.8%, its largest single-day gain in a year, the same day its depositary receipt program was due to end and its Class A shares began trading directly on Nasdaq.
POMDOCTOR is a Guangzhou-based digital healthcare company focused on chronic disease management and predictive healthcare. It has two segments, internet hospital services and a pharmaceutical supply chain, and the supply chain generates most of its revenue.
Share Switch and Consolidation: What Changed on October 21?
In an announcement dated October 19, 2026, the company said it would terminate its American depositary receipt program and move to trading Class A ordinary shares directly on Nasdaq. The board approved the plan on September 3, 2026, and shareholders gave advisory approval at a meeting on September 30, 2026.
A 10-for-1 consolidation applies to both Class A and Class B shares. Holders of 10 depositary receipts receive 3 post-consolidation Class A shares, and the symbol POM is unchanged.
Share-count changes of this kind reset the quoted price and can produce large percentage moves in the first sessions, particularly when the share count is small. About 9.3 million shares are outstanding, which implies a market value near $14.1 million at $1.52 (calculated).
Nasdaq Compliance and Going Concern: Why Does the Backdrop Matter?
On October 9, 2026, the company filed that it intended to appeal after its shares traded below $1.00 for 30 business days. That followed a delisting determination from Nasdaq staff, and the company has not announced the outcome of the appeal.
In a filing dated September 29, 2026, the company reported higher revenue but flagged substantial doubt about its ability to continue as a going concern.On September 30, 2026, it announced an effort to speed up AI-enabled chronic disease management and the commercial use of real-world healthcare data.
Financial Context: How Large Is the Business?
Fiscal 2025 revenue was $57.2 million, and the net loss was $18.7 million, or $3.14 per diluted share. At the current market value, the company trades at about 0.25 times fiscal 2025 revenue (calculated).
The net loss equals about 33% of revenue (calculated). Market value was roughly $18.4 million at the $1.99 level reported on October 22, against the $14.1 million estimate above (calculated).
What to Watch Next: Will the Appeal Keep POMDOCTOR on Nasdaq?
POMDOCTOR fell 25.12% on October 23, 2026, after a 352.8% surge on October 21, with no company announcement tied to the decline. The key open items are the outcome of the Nasdaq appeal and whether the stock holds above $1.00 after the consolidation. The company has not announced a hearing date or its next results report.
The shares fell 25.12% to $1.52, and the company has not announced a catalyst; the move followed a 352.8% surge on October 21.
The program was due to end before the open on October 21, 2026, with Class A ordinary shares trading directly on Nasdaq under POM.
Revenue was $57.2 million, with a net loss of $18.7 million.






Please wait processing your request...